BETA — Beta Drugs Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapHigh Flyer

Annual income statement for Beta Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,161	1,838	2,271	2,957	3,624
Cost of Revenue
Gross Profit	439	716	971	1,145	1,504
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	982	1,484	1,841	2,456	3,048
Operating Profit	179	354	430	501	575
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	160	343	411	488	570
Provision for Income Taxes
Net Income After Taxes	117	248	307	364	424
Net Income Before Extraordinary Items
Net Income	117	248	307	364	424
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	117	248	307	364	424
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	12.2	25.8	32	37.9	45.4